We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Disrupted Micronuclei Cited as Potential Non-Small-Cell Lung Cancer Biomarkers

By LabMedica International staff writers
Posted on 16 Jul 2013
Cancer researchers have found that collapse of the nuclear membrane that surrounds micronuclei—bits of the genome that become detached during cell replication—may allow these damaged segments of DNA to reenter the cell's genetic material with possible cancer-causing consequences.

Investigators at the Salk Institute for Biological Sciences (La Jolla, CA, USA) worked with cultures of non-small-cell lung cancer (NSCLC) cells. More...
They reported in the July 3, 2013, issue of the journal Cell that micronuclei, which were sometimes generated when these cells replicated, had reduced functioning compared to primary nuclei in the same cell, although the two compartments appeared to be structurally comparable. Over 60% of micronuclei were found to undergo an irreversible loss of compartmentalization during interphase due to collapse of their nuclear envelope.

The disruption of the micronuclei, which was induced by defects in nuclear lamina assembly, drastically reduced nuclear functions and had the potential to trigger massive DNA damage. Disruption of micronuclei was associated with chromatin compaction and invasion of endoplasmic reticulum (ER) tubules into the chromatin.

Disrupted micronuclei were detected in both major subtypes of NSCLC, suggesting that this feature could be a useful objective biomarker for genomic instability in solid tumors.

"Our study shows that more than 60% of micronuclei undergo catastrophic dysfunction in solid tumors such as NSCLC," said senior author Dr. Martin Hetzer, professor of molecular and cell biology at the Salk Institute for Biological Sciences. "We identified disrupted micronuclei in two major subtypes of human non-small-cell lung cancer, which suggests that they could be a valuable tool for cancer diagnosis."

Related Links:
Salk Institute for Biological Sciences



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.